Evidence map›Paper›PMID 31230189›Full record

Observational studyClinical and experimental nephrology2019

Risk factors for relapse and long-term outcome of idiopathic retroperitoneal fibrosis.

Diego Moriconi, Domenico Giannese, Riccardo Capecchi, Adamasco Cupisti, Simone Barsotti, Riccardo Morganti, Eugenio Orsitto, Antonio Gaetano Tavoni, Maria Francesca Egidi

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Clinical and experimental nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 29 citations in OpenAlex.

  1. Multimodality imaging review of retroperitoneal fibrosis.Abdominal radiology (New York) · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Renal Involvement in Retroperitoneal Fibrosis: Prevalence, Impact and Management Challenges.International journal of nephrology and renovascular disease · 2021
    Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Diego MoriconiDepartment of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa, Italy. diego.moriconi@yahoo.com.
Domenico GianneseNephrology, Dialysis and Transplantation AOUP Pisa, Pisa, Italy.
Riccardo CapecchiDepartment of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa, Italy.
Adamasco CupistiDepartment of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa, Italy.
Simone BarsottiDepartment of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa, Italy.
Riccardo MorgantiSection of Statistics, AOUP Pisa, Pisa, Italy.
Eugenio OrsittoRadiology Unit, Emergency Department, AOUP Pisa, Pisa, Italy.
Antonio Gaetano TavoniDepartment of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa, Italy.
Maria Francesca EgidiNephrology, Dialysis and Transplantation AOUP Pisa, Pisa, Italy.
University of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRetroperitoneal fibrosis (RF) is a rare disease of unclear etiology characterized by the presence of fibroinflammatory tissue in the retroperitoneal space, which can entrap and obstruct retroperitoneal structures, notably the ureters. The disease responds well to steroid therapy, but tends to recur even after years. The aim of our study was to evaluate the long-term renal outcome of patients affected by idiopathic retroperitoneal fibrosis looking for predictive risk factors for recurrence of the disease and progression to end-stage renal disease.

methodsRetrospective observational study of patients with idiopathic RF diagnosed from 2004 to 2017 and follow-up of at least 1 year after the end of first course therapy with steroid, with or without tamoxifen (TMX) and with urological procedures when applicable.

resultsForty-three patients were included in the study. The follow-up was 93 ± 52 months. All the patients obtained remission after therapy that was maintained until the last observation in 26 of them. In 17 patients, there was at least one recurrence. Risk factors associated with relapse were identified and resulted in smoking habit, onset with acute kidney injury (AKI), low back pain and antinuclear antibodies (ANA) positivity. Renal function remained fairly stable during the long-term follow-up. The renal end-point (doubling of serum creatinine or ESRD) occurred in 8% of the patients; however, eGFR in patients with relapse was similar to that of non-recurrent at the diagnoses, but it decreased over time more in the relapsing than in non-relapsing patients (p group = 0.20; p time = 0.001; p time × group interactions = 0.04). Based on these 4 predictor conditions, patients were divided into "low risk" (with 0-1 risk factor), and "high risk" (3-4 risk factors). The renal end-point occurred in 40% of high-risk patients, while none of the low-risk patients reached it (p = 0.02).

conclusionsSmoking habit, AKI at diagnosis, ANA positivity and lumbar pain were associated with relapse of RF after initial remission due to steroid and/or TMX therapy; the combination of these conditions was also predictive of worse renal function outcome. Identification of risk factors for relapse can be useful not only to modulate the choice, the dosage of first-line treatment and the duration of maintenance therapy but also for preventing a progressive loss of kidney function, as well.

Indexed as

Urologic Surgical ProceduresAcute Kidney InjuryAdultAgedAntibodies, AntinuclearDisease ProgressionFemaleHumansKidney Failure, ChronicLow Back PainMaleMiddle AgedRecurrenceRemission InductionRetroperitoneal FibrosisRetrospective StudiesAntibodies, AntinuclearSteroidsTamoxifenKidney outcomePredictors of relapseRetroperitoneal fibrosis

Identifiers

PMID31230189
OpenAlexW2952213773

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.